The present invention relates to a method o f quantifying the amount of Mock Virus Particles (MVP) removed from a solution as a result of processing that solution through a purification technique. This method involves the steps of adding MVP to a solution, processing the solution through a purification technique, quantifying the amount of MVP removed from the solution. The present invention also relates to a kit that can be used in conjunction with the method. This kit will comprise at least one stock solution of MVP and at least one quantification solution.

Assays and diagnostic devices for rapidly distinguishing between bacterial or viral sources of infection in a biological sample from mammalian subject are provided. A biological sample from said subject is contacted with a diagnostic reagent that detects at least one, or a pattern of multiple, volatile organic compounds (VOC). Detection of the VOC or a pattern of said VOC indicates a single source of infection selected from a Gram-positive bacterial infection, a Gram-negative bacterial infection, or a viral infection. In one embodiment, a dipstick diagnostic device permits rapid discrimination between bacterial or viral infection based upon the reaction of a detectable VOC reactive compound and optional label positioned on the dipstick surface.

The present invention provides a composition for multiplex diagnosis of Toxoplasma gondii and/or influenza virus, comprising virus-like particles (VLPs) that comprise a T. gondii surface antigen protein, and VLPs that comprise an influenza virus M1 protein. In one embodiment, the VLPs comprise at least one protein from the group consisting of TgAMA1 VLP, TROP4 VLP and TgROP18. The composition for multiplex diagnosis can react, with high sensitivity and specificity, to biological samples isolated from individuals infected with T. gondii and individuals infected with Influenza virus. Therefore, the composition for multiplex diagnosis can be used in a kit for multiplex diagnosis of toxoplasmosis and/or Influenza virus.

Methods of using mesothelin levels is provided.

A flavivirus Envelope Dimer Epitope (EDE) and isolated neutralizing antibody or antigen binding fragment thereof directed against the EDE for use in vaccinating an individual against one or more flaviviruses wherein the EDE is a stabilized recombinant flavivirus are provided. The dimer is: covalently stabilized with at least one disulphide inter-chain bond or one sulfhydryl-reactive crosslinker between the two sE monomers, and/or by being formed as a single polypeptide chain, and/or by linking the two sE monomers through modified sugar, and/or non-covalently stabilized by substituting at least one amino acid residue in the amino acid sequence of at least one sE monomer with at least one bulky side chain amino acid, at the dimer interface or in domain 1 (D1)/domain 3 (D3) linker of each monomer. The dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from DENV-1, DENV-2, DENV-3, DENV-4, Zika and/or other flavivirus.

The invention relates to multispecific antibodies, and antigen binding fragments thereof, that specifically bind to distinct Zika virus epitopes and potently neutralize infection of ZIKV. The invention also relates to nucleic acids that encode such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in prophylaxis and treatment of ZIKV infection.

The present invention relates to an aptamer not binding to the receptor-binding domain of the SARS-CoV-2 spike glycoprotein nor inhibiting the interaction of the receptor-binding domain (RED) of spike glycoprotein with angiotensin-converting enzyme II (ACE2) and/or comprising or consisting of a nucleotide sequence SEQ ID NO: 1, a composition comprising the aptamer, and the use of the aptamer in the detection of SARS-CoV-2 or diagnosis or treatment of a SARS-CoV-2 infection.

The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.

Methods and devices for detecting and diagnosing the etiological agents associated with Canine Infectious Respiratory Disease Complex in animals, such as kennel cough, are disclosed herein.

Alternative antibodies to screen for SARS-CoV-2 are disclosed. One alternative antibody is Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1056 (E3-Antibody or E3), from EastCoast Bio, Inc., PO Box 489, North Berwick, ME 03906, USA (EastCoast Bio). Another alternative antibody is a combination of the E3-Antibody and Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1057 (E1-Antibody or E1), from EastCoast Bio (the combination of the E1-Antibody and the E3-Antibody is designated as E1/E3-Antibody or simply E1/E3). Yet another alternative antibody is a combination of Mouse Species Anti-SARS-CoV-2 NP mAb, clone 4B21, Catalog Number CABT-CS027 (C4-Antibody or C4), from Creative Diagnostics, 45-1 Ramsey Road, Shirley, NY 11967, USA (Creative Diagnostics), and Mouse Species Anti-SARS-CoV-2 NP mAb, clone 7G21, Catalog Number CABT-CS026 (C5-Antibody or C5), also from Creative Diagnostics (the combination of the C4-Antibody and the C5-Antibody is designated as C4/C5-Antibody or simply C4/C5).